Ocular Hypertension - Pipeline Insight, 2024

This “Ocular Hypertension- Pipeline Insight, 2024” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Ocular Hypertension pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Ocular Hypertension: Understanding

Ocular Hypertension: Overview

Ocular hypertension occurs when the pressure inside the eye exceeds the range considered normal and goes higher than 21 mm Hg. The increase in intraocular pressure (progressive with age, although may also be due to other disorders or causes) is the main risk factor for developing glaucoma and, therefore, people with ocular hypertension are more likely to suffer the disease. However, the two are different: ocular hypertension means that the intraocular pressure is high but the optic nerve is not damaged, whereas with glaucoma, the optic nerve has been damaged - and intraocular pressure might be normal or high - which can lead patients to notice a loss of visual field and even central vision in advanced stages of the disorder.

In the United States, the prevalence of ocular hypertension in non-Hispanic Whites who are 40 years of age and older is 4.5 percent, and increases up to 7.7 percent in 75 to 79 year olds. In Latinos, the prevalence across ages is quite similar. Because ocular hypertension occurs typically without symptoms, a majority of people with ocular hypertension remains undiagnosed. In the Los Angeles Latino Eye Study, 75 percent of Latinos with eye pressures greater than 21 mmHg were previously undiagnosed. Ocular hypertension is caused by a malfunction of the drainage system for the aqueous humour, the fluid whose function is to bathe and nourish the ocular structures. When it does not flow correctly for different reasons, the balance between the fluid produced inside the eye and the fluid released from it is broken, leading to an increase in intraocular pressure (normally gradual, although it may also be sudden).

For diagnosis of OHT, patients should be offered the following tests: central visual field assessment using standard automated perimetry; optic nerve assessment and fundus examination using stereoscopic slit lamp biomicroscopy (with pupil dilatation if necessary); optical coherence tomography (OCT) or optic nerve head imaging; intraocular pressure (IOP) measurement using Goldmann-type applanation tonometry; peripheral anterior chamber configuration and depth assessments using gonioscopy.

The most usual type of treatment to be prescribed is eye drops that control the pressure within the eye, (these are the same drugs that are used to control glaucoma) by either reducing the amount of aqueous humour being produced by the eye (the ciliary body) or increasing the rate of drainage. There have been major advances in these forms of treatments in recent years and eye drops are now more effective and have fewer side effects than those that were previously available. Medications to lower pressure in your eyes include- Prostaglandins, Beta-blockers, Alpha-adrenergic agonists, Carbonic anhydrase inhibitors, Rho kinase inhibitor, and Miotic or cholinergic agents, among others. In some cases (or if eye drops are ineffective in reducing IOP), other glaucoma treatment measures, including glaucoma/laser surgery could be recommended, to treat high eye pressure. The bottom line is that a patient with ocular hypertension should have long-term follow-up with the physician to monitor the potential development of glaucoma or to gauge the effectiveness of treatments that are implemented.

Ocular Hypertension- Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Ocular Hypertension pipeline landscape is provided which includes the disease overview and Ocular Hypertension treatment guidelines. The assessment part of the report embraces, in depth Ocular Hypertension commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Ocular Hypertension collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Ocular Hypertension R&D. The therapies under development are focused on novel approaches to treat/improve Ocular Hypertension.

Ocular Hypertension Emerging Drugs Chapters

This segment of the Ocular Hypertension report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Ocular Hypertension Emerging Drugs

NCX-470: Nicox NCX 470, is a novel nitric oxide (NO)-donating bimatoprost eye drop, currently in Phase III clinical development for the lowering of intraocular pressure (IOP) in patients with open angle glaucoma or ocularhypertension.

It is a novel nitric oxide (NO)-donating bimatoprost eye drop that leverages the potent intraocular pressure (IOP)-lowering effects of NO and prostaglandin analogs (PGAs). NCX 470 incorporates Nicox’s proprietary NO-donating research platform and bimatoprost in a single molecule. It is designed to release bimatoprost and NO into the eye to lower IOP by two different pathways in patients with open-angle glaucoma or ocular hypertension.

QLS-101: Qlaris Bio QLS-101 is an investigational therapy, designed to lower intraocular pressure (IOP) by reducing episcleral venous pressure (EVP) in individuals with glaucoma. It is currently in Phase II trial in adolescents with Sturge-Weber syndrome (SWS) who have clinical evidence of glaucoma and/or ocular hypertension (OHT) related to SWS elevated EVP in at least oneeye.

It is a novel adenosine triphosphate (ATP)-sensitive potassium (KATP) channel modulator administered as a topical eyedrop. Beyond its potential utility as an effective monotherapy or additive therapy for the lowering of IOP in primary open angle glaucoma (POAG), QLS-101 may represent a new treatment paradigm in additional populations where current IOP-lowering therapies are inadequate, including normal-tension glaucoma (NTG) and patients with Sturge-Weber syndrome (SWS, a rare pediatric disease).

TO-O-1001: Therat Ocular Biotek Co., Ltd.TO-O-1001 (Formerly known as MG-O-1001) eye drops is a patented new generation Rho kinase (ROCK) inhibitor for treating patients with primary open-angle glaucoma or ocular hypertension. Its therapeutic potency is established through a dual-targeting mechanism, which in turn leads to relaxation of the cells of trabecular meshwork and the inner walls of Schlemm’s canal. It is currently in Phase I/II for Patients with Open-Angle Glaucoma or OcularHypertension.

Its unique features include novel and proven working mechanism, good for used alone or in combination with the other IOP-lowering agents, best in class as the ROCK inhibition is a proven clinical approach for lowering IOP, animal studies showed superior efficacy results in IOP-lowering than the current market leader, and user-friendly as once a day.

Ocular Hypertension: Therapeutic Assessment

This segment of the report provides insights about the different Ocular Hypertension drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Ocular Hypertension

There are approx. 70+ key companies which are developing the therapies for Ocular Hypertension. The companies which have their Ocular Hypertension drug candidates in the most advanced stage, i.e. phase III include, Deerland Probiotics & Enzymes.

Phases

This report covers around 75+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Ocular Hypertension pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Ocular Hypertension: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Ocular Hypertension therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ocular Hypertension drugs.

Ocular Hypertension Report Insights

• Ocular Hypertension Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Ocular Hypertension Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Ocular Hypertension drugs?
• How many Ocular Hypertension drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Ocular Hypertension?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Ocular Hypertension therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Ocular Hypertension and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Nicox
• Qlaris Bio
• Therat Ocular Biotek Co.,Ltd.
• Ocular Therapeutix
• Whitecap Biosciences, LLC
• Jeni Vision,Inc.
• AbbVie

Key Products

• NCX-470
• QLS-101
• TO-O-1001
• OTX-TIC
• WB007
• JV-GL1
• AGN-193408

This product will be delivered within 1-3 business days.